FDA Approvals, Public Offerings and Stock Price Movements - Research Report on BioMarin, AEterna Zentaris, Charles River, Anika Therapeutics and Halozyme Therapeutics

NEW YORK, November 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), AEterna Zentaris Inc. (NASDAQ: AEZS), Charles River Laboratories (NYSE: CRL), Anika Therapeutics, Inc. (NASDAQ: ANIK) and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On November 19, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. FDA voted in favor of approval of Vimizim towards the treatment of Morquio A syndrome (Mucopolysaccharidosis Type IVA/MPS IVA). Jean-Jacques Bienaimé, CEO of BioMarin, commented, "We are thrilled to have achieved this important milestone in our mission to bring the first approved therapy to treat Morquio A patients.  I am very pleased with the outcome of today's panel vote and look forward to continuing to work with the FDA to bring this much-needed therapy to these patients." Vimizim stated that this is an investigational enzyme replacement therapy for the treatment of patients with the lysosomal storage disorder Morquio A syndrome - an ultra-rare, severely debilitating disease that affects an estimated 3,000 patients in the developed world. The Company informed that the FDA has assigned February 28, 2014 as Prescription Drug User Fee Act action date for completion of its review of the Biologics License Application for Vimizim. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

--

AEterna Zentaris Inc. Research Report

On November 20, 2013, AEterna Zentaris Inc. (AEterna Zentaris) announced the pricing of its previously announced public offering of 13.1 million units (the Offering), at a purchase price of $1.15 per unit, with each unit consisting of one common share and one whole warrant to purchase one common share. The Company stated that each warrant will be exercisable for a period of five years after the issuance at an exercise price of $1.60 per share. AEterna Zentaris expects net proceeds from the Offering to be approximately $13.7 million, after deducting underwriting commissions and other expenses related to the Offering. The Company plans to use net proceeds from the Offering to continue funding its ongoing drug development activities, for the potential addition of commercialized products to the Company's pipeline, future negative cash flow, general corporate purposes and working capital. AEterna Zentaris stated that the Offering is expected to close on or about November 25, 2013, subject to customary closing conditions. The Full Research Report on AEterna Zentaris Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3499_AEZS

--

Charles River Laboratories Research Report

On November 20, 2013, stocks of Charles River Laboratories (Charles River) rose 0.53% to end the day at $51.51. Over the past three trading sessions, shares of Charles River slipped 0.43% as compared to the Dow Jones Industrial Average, which dropped 0.38% during the same period. The Full Research Report on Charles River Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a37e_CRL

--

Anika Therapeutics, Inc. Research Report

On November 20, 2013, Anika Therapeutics, Inc's (Anika Therapeutics) stock rose 1.13% to $31.22 at the end of trading session. Share of Anika Therapeutics have dipped 0.10% over the past three trading sessions, while the Dow Jones Industrial Average fell 0.38% during the same period. The Full Research Report on Anika Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ae5d_ANIK

--

Halozyme Therapeutics, Inc. Research Report

On November 20, 2013, shares of Halozyme Therapeutics, Inc. (Halozyme) slipped 0.53% to end the day at $13.10. Shares of Halozyme dropped 3.18% over the previous three trading session, while the NASDAQ composite dropped 1.62% during the same period. The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner